Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 56Fallopian Tube Neoplasms 25Breast Neoplasms 18Neoplasms 14Carcinoma, Ovarian Epithelial 14Multiple Myeloma 9Neoplasm Metastasis 7Triple Negative Breast Neoplasms 3Recurrence 3Peritoneal Neoplasms 3Lung Neoplasms 3Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Carcinoma 3Solid Tumors 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Pancreatic Neoplasms 2Ovarian Cancer Recurrent 2Liver Neoplasms 2Kidney Neoplasms 2Endometrial Neoplasms 2Disease Progression 2Vaccinia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Sarcoma 1

Interventions

Gemcitabine 2serotonin adipinate 1liposomal doxorubicin 1Serotonin 1Paclitaxel 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Pelvic Neoplasms × liposomal doxorubicin × Clear all
NCT00191607 2007-01-26

A Randomized Trial for Patients With Platinum Resistant Ovarian, Fallopian or Primary Peritoneal Cancer.

Eli Lilly and Company

Phase 3 Completed
162 enrolled
Gynecologic

Fallopian Tube Neoplasms, Genital Neoplasms, Female, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡